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Introduction: Treatment-resistant nephrotic syndrome is a rare form of glomerular disease that occurs in
children and adults. No Food and Drug Administrationapproved treatments consistently achieve
remission of proteinuria and preservation of kidney function. CD80 (B7-1) can be expressed on injured
podocytes, and administration of abatacept (modiﬁed CTLA4-Ig based on a natural ligand to CD80) has
been associated with sustained normalization of urinary protein excretion and maintenance of glomerular
ﬁltration rate in experimental and clinical settings.
Methods: In this report, we describe the rationale for and design of a randomized, placebo-controlled,
clinical trial of abatacept in patients with treatment-resistant nephrotic syndrome caused by focal
segmental glomerulosclerosis or minimal change disease. The design is a hybrid of a parallel-group and
crossover design (switchover) with the primary objectives assessed in the ﬁrst period of the study and the
secondary objectives assessed using data from both periods. All participants will receive the active agent
in 1 of the periods. The duration of treatment will be 4 months per period.
Results: The primary outcome will be improvement in nephrotic-range proteinuria to subnephrotic range,
that is, reduction from baseline to 4 months in urine protein:creatinine ratio $ 50% and to a level < 3. The
projected sample size is 90 patients, which has 80% power to detect a treatment difference of 28%.
Conclusion: This study advances efforts to validate CD80 as a therapeutic target for treatment-resistant
nephrotic syndrome, and implements a precision medicine-based approach to this serious kidney con-
dition in which the selection of a therapeutic agent is guided by the underlying disease mechanism
operating in individual patients.
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CLINICAL ASPECTS
F ocal segmental glomerulosclerosis (FSGS) and mini-mal change disease (MCD) are clusters of syndromes
that can present with asymptomatic proteinuria, in
either the subnephrotic or the nephrotic range, or with
nephrotic syndrome in children and adults. The terms
MCD and FSGS are histopathologically deﬁned and are
descriptive of processes that, at least in the early stages,
cause either no scarring (MCD) or segmental scarring in
some glomeruli (FSGS). Over time, more glomeruli are
involved, and some manifest global scars. MCD is the
most commondiagnosis in children, and a subset of these
children fully respond to glucocorticoid treatment with
no further complications or sequelae (“treatment-sensi-
tive” disease). Our study focuses on the signiﬁcant
proportion of children or adults with an MCD or FSGS
biopsy diagnosis who do not respond to glucocorticoids
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CLINICAL RESEARCH
and/or other treatments, and therefore have “treatment-
resistant” nephrotic syndrome (TRNS). These patients
are at the greatest risk for progression to end-stage kid-
ney disease (ESKD).1
The terms MCD or FSGS do not provide any mech-
anistic insight into the cellular or molecular mecha-
nisms leading to disease. There is ongoing debate as to
whether MCD and FSGS are entities along a spectrum of
disease from minimal injury to extensive sclerosis.
Recent studies have implicated kidney podocyte injury
or death as the initial step in the development of focal
and segmental scarring of glomeruli.2 Understanding
that there may be other unidentiﬁed pathways, there
are currently 3 potential mechanisms of disease in pa-
tients with MCD/FSGS that can cause proteinuria and
progressive glomerular injury: (i) a genetic mutation in
a podocyte protein leading to an alteration in cell
structure and function; (ii) a circulating factor(s) that
increases glomerular permeability to protein; and (iii)
adaptive changes in the podocyte in response to a
variety of insults including nephron loss and metabolic
disorders.2,3 Other causes include viral infection,
including HIV and certain medications.
First-line treatment in patients with MCD/FSGS is an
angiotensin-converting enzyme inhibitor or an angio-
tensin receptor blocker.4 In patients with overt
nephrotic syndrome, glucocorticoids are also a common
component of ﬁrst line therapy. Calcineurin inhibitors
(CNIs) are recommended for patients who fail to
respond to glucocorticoids, for those who relapse, and
for those with a contraindication to corticosteroids.5
The prognosis in patients who are unresponsive to
glucocorticoids and/or CNIs is poor, with an estimated
50% progressing to ESKD over 5 to 10 years of follow-
up. In regional and national registries of kidney dis-
ease, MCD/FSGS accounts for 10% to 15% of ESKD
cases in pediatric and adult patients. Finally, nearly
25% of patients undergoing a kidney transplantation
for FSGS induced-ESKD will develop recurrent FSGS in
the allograft.5 Thus, treatment-resistant MCD/FSGS
represents a rare but signiﬁcant cause of morbidity and
mortality, and remains a largely untreatable disease.
Developing proven therapies that retard progression of
this glomerular disease represents a large unmet need
in clinical nephrology.
BIOLOGY, TARGET AND AGENT RATIONALE
Glomerular podocytes, with their foot processes and
interposed slit diaphragms, serve as the ﬁnal barrier to
urinary protein loss. Disrupted podocyte function
damages the kidney ﬁlter, leading to proteinuria and
nephrotic syndrome.6 Clinically, proteinuria is the
common denominator of a heterogeneous group of
diseases, termed podocytopathies, which includes
MCD, FSGS, and membranous nephropathy.6
Cluster of differentiation 80 (CD80 and B7-1) is a
protein found on the surface of a variety of immu-
noeffector cells including dendritic cells, activated B
cells, and monocytes. It provides a costimulatory signal
necessary for T-cell activation and survival. It is the
ligand for 2 different proteins on the T-cell surface:
CD28 (for autoregulation and intercellular association)
and CTLA-4 (for attenuation of regulation and cellular
disassociation). CD80 works in tandem with CD86 to
prime T cells.7
Podocyte CD80 induction is associated with devel-
opment of proteinuria in human lupus nephritis,
murine lupus nephritis, b3-integrin knockout mice,
nephrin knockout mice, and murine lipopolysaccharide
(LPS)induced proteinuria.8 Yu et al.9 reported
induction of podocyte CD80 in biopsy samples of
patients with nephrotic syndrome, including primary
and recurrent FSGS. Thus, they introduced the idea
that CD80 staining may serve as a biomarker to facili-
tate the diagnosis and targeted treatment of proteinuric
kidney diseases. Treatment with abatacept (modiﬁed
CTLA4-Ig), a speciﬁc CD80 antagonist currently
approved for the treatment of rheumatoid arthritis,
juvenile idiopathic arthritis, and psoriatic arthritis,10
induced a durable remission of proteinuria in 4
patients with rituximab-resistant recurrent FSGS in
renal allografts and achieved on-drug complete remis-
sion in 1 patient with primary treatment-resistant
nephrotic syndrome in the native kidneys.9
Is podocyte CD80 induction a characteristic of other
proteinuric kidney diseases such as diabetic nephrop-
athy,11,12 and does it represent a ﬁnal common pattern
of injury? Unfortunately, our ability to answer these
questions has been limited by the lack of speciﬁcity
and sensitivity of CD80 staining in human kidney
biopsy samples, a procedure that has been found to be
technically difﬁcult and prone to misinterpretation.
First, antibodies to CD80 have been notoriously difﬁ-
cult to work with since the early days of its discovery.
Second, the abundance of CD80 in podocytes, even
after injury and stress, is modest, and so there is a
limited dynamic range for immune-detection methods.
Third, the CD80 epitope(s), detectable only in fresh-
frozen tissue, appears to readily degrade over time
even under storage conditions that preserve other
antigens, leading to false-negative results (S. Hewitt,
personal communication). These technical consider-
ations suggest that the contribution of CD80 to
glomerular disease may be underestimated. Thus, the
number of patients with treatment-resistant proteinuria
in whom podocyte CD80 positivity renders them can-
didates for abatacept treatment may exceed the number
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deﬁned by current immunohistochemical staining
methods. It is anticipated that ongoing work using
novel antibodies, speciﬁc staining protocols, and
advanced imaging techniques will enable more accurate
delineation of the proportion of proteinuric kidney
disease patients who are “CD80 positive.” A retro-
spective study in the pathology archives of a single
center found that “CD80-positive” proteinuric kidney
disease patients represent approximately 30% of all
kidney biopsies with treatment-resistant proteinuria.9
Recent efforts at urinary detection of CD80 are also
encouraging,13–15 suggesting that this approach, once
the procedure is optimized, may be complementary or
superior to the detection of CD80 in kidney biopsy
material.
In the absence of a clinically validated biomarker,
we have decided to proceed with testing the clinical
efﬁcacy of abatacept in a clinically well-deﬁned pop-
ulation of individuals with treatment-resistant
nephrotic syndrome, in the hopes of detecting a sufﬁ-
cient signal to merit further study in a future, targeted,
biomarker-driven trial. These assumptions and the
importance of collecting appropriate samples for CD80
biomarker derivation and validation studies in
responders versus nonresponders in this trial informed
the study design.
CLINICAL TRIAL DESIGN
Study Objectives
Primary Objective
The main aim is to compare whether abatacept, relative
to placebo, improves proteinuria (from nephrotic range
to subnephrotic range) while maintaining renal func-
tion in patients with TRNS presenting as native disease
(in contrast to recurrent disease after transplantation).
This will be assessed by the difference in the per-
centage of participants who achieve a renal response
(a composite renal index at day 113). The renal index is
deﬁned as achieving all of the following components:
(i) a$ 50% reduction from baseline to day 113 in urine
protein:creatinine ratio (UPCR); (ii) day 113 UPCR < 3
g/g; and (iii) estimated glomerular ﬁltration rate (eGFR)
at day 113 remaining normal (deﬁned as > 90 ml/min
per 1.73 m2) or if below normal at baseline,
remaining $ 75% of baseline.
Secondary Objectives
Abatacept and placebo will be compared for the
following secondary outcomes: (i) change in protein-
uria, deﬁned as the difference in mean change in UPCR
from baseline to day 113; (ii) change in serum albumin
levels, deﬁned as the difference in mean change in
serum albumin from baseline to day 113; (iii) occur-
rence of complete remission while maintaining renal
function, deﬁned as the difference in percentage of
participants achieving complete remission (UPCR < 0.3
g/g) with preservation of eGFR (as deﬁned above) at
day 113; (iv) change in age-appropriate patient-re-
ported outcomes related to nephrotic syndrome
assessed by the Patient Reported Outcomes Measure-
ment Information System (PROMIS) items for physical
function, fatigue, and pain interference; (v) percentage
of participants with adverse events and serious adverse
events; (vi) immunogenicity testing parameters (only
for abatacept-treated participants); and (vii) pharma-
cokinetics of abatacept.
Study Population
Participants will be recruited from more than 20
participating centers in the United States. Participants
who enroll will meet the inclusion and exclusion
criteria described below.
Key Inclusion Criteria
Key inclusion criteria are as follows: (i) male and female
participants, aged $ 6 years; (ii) participants diagnosed
with TRNS (FSGS/MCD), excluding collapsing FSGS
conﬁrmed by central pathology review; (iii) preserved
renal function as deﬁned by eGFR $ 45 ml/min per
1.73 m2 for both adults and children, calculated based
on the CKD-EPI formula for adults and the bedside
Schwartz equation for children16; (iv) nephrotic syn-
drome deﬁned as UPCR $ 3 (g/g) at screening; (v)
treatment-resistant nephrotic syndrome (TRNS) deﬁned
as persistence of UPCR $ 3 despite therapy with any 1
of the following agents: glucocorticoids, CNI (cyclo-
sporine and tacrolimus), sirolimus, mycophenolate
mofetil, mycophenolic acid, or cyclophosphamide. In
this study, the term “resistance” applies to participants
with both primary and secondary resistance to gluco-
corticoids and to responders who have unacceptable
treatment-related toxicities. The duration of glucocor-
ticoid therapy required to determine treatment
resistance will be a minimum of 6 weeks in
participants < 18 years of age and 12 weeks for
participants $ 18 years. For all other agents, the min-
imum duration of therapy will be 16 weeks, regardless
of age or intolerance to any 2 of these agents, regardless
of duration of treatment or age. (vi) Stable dose of
currently prescribed MCD/FSGS therapy for at least 4
weeks.
Key Exclusion Criteria
Key exclusion criteria are as follows: (i) participants
with causes of TRNS other than FSGS or MCD (e.g., IgA
nephropathy or membranous nephropathy, lupus
nephritis); (ii) participants with diabetes mellitus, both
type 1 and type 2; (iii) participants with clinically
signiﬁcant congestive heart failure (CHF; New York
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Heart Association Class III or Class IV); (iv) body mass
index (BMI) > 40 for adults or > 99th percentile for
pediatric participants that is not related to ﬂuid
retention; (v) recent active infection, tuberculosis, HIV,
or hepatitis B or C infection; (vi) any test results that, in
the opinion of the investigator, might place the
participant at unacceptable risk for participation in this
study.
Study Design
This study represents collaboration between the
industry sponsor and a network of academic centers
with experience in the performance of randomized
clinical trials for patients with glomerular disease and
speciﬁcally TRNS, MCD/FSGS. The team includes
clinical trialists, translational scientists, clinicians in
nephrology and rheumatology, pathologists, and bio-
statisticians. The partners jointly designed the study
protocol and will participate as members of the Steering
Committee to oversee the conduct of the trial, in
addition to a data-monitoring committee.
This pilot study will enroll approximately 90 par-
ticipants who will be randomized 1:1 to receive i.v.
abatacept or placebo in a double-blind fashion into 2
parallel arms with a switchover study design. Study
drug will be administered following labeled-dosing
previously established age and weight-based guide-
lines for rheumatoid arthritis and juvenile idiopathic
arthritis. The trial will consist of 4 phases: (i) a 28-day
screening period (can be extended an additional 14
days to complete testing by repeating screening labo-
ratory tests); (ii) a 16-week treatment period 1 (parallel
arms: i.v. abatacept or placebo given on days 1, 14, 28,
and every 28 days thereafter); (iii) a 16-week treatment
period 2 (in which participants receive the alternative
study medication [i.e., a switchover in treatment]
according to the same administration schedule as in
period 1); and (iv) a 169-day abatacept open-label
extension (OLE) period (Figure 1). Following comple-
tion of the OLE, subjects deriving clinical beneﬁt from
the use of abatacept will be eligible to receive ongoing
poststudy drug in an access program supported by the
study’s sponsor.
Written informed consent will be provided by the
participants prior to undergoing any procedures dur-
ing the screening phase. The primary efﬁcacy assess-
ment of renal response will be on day 113 (end of
period 1). On day 113, participants will enter period 2
and switch treatment groups. Participants in the aba-
tacept arm (cohort I) will switch to placebo, and
placebo-treated participants (cohort II) will switch to
abatacept. By receiving abatacept in period 2, cohort II
will be used to conﬁrm the response rate observed in
period 1. Cohort I will establish the permanence of
effect by monitoring the occurrence of relapses in
responders from period 1 off abatacept. Efﬁcacy out-
comes from period 2 will be for descriptive purposes,
whereas safety outcomes from period 2 will contribute
to our overall safety assessment. Starting on day 169,
participants who relapse in period 2 will be able to
escape their study treatment and receive open-label
abatacept therapy by entering the OLE. Participants
who complete the trial per protocol may access abata-
cept therapy by entering the OLE period for up to 169
days. During the OLE period, the durability (i.e.,
continuous response) and stability (i.e., variability in
the improvement in UPCR) of response will be deter-
mined by continuing to capture the same study out-
comes among responders on a monthly basis, during
patient visits designed to coincide with drug infusions.
Withdrawal or modiﬁcation of background therapy
will also be allowed during the OLE at the discretion of
the investigators and participants to determine the
relative contribution (or need) of these agents for renal
responses.
Concomitant Therapy
Patients with TRNS are usually treated with a variety
of drugs that are designed to reduce proteinuria,
including speciﬁc immunosuppressive agents and
nonspeciﬁc antihypertensive and lipid-lowering
agents. During the study, participants will be allowed
to continue the background concomitant therapy for
TRNS with low-dose glucocorticoids (prednisone or
Figure 1. Schematic representation of the study design. The trial will
consist of 5 periods: the screening period will be 28 days (can be
extended an additional 14 days to complete testing by repeating
screening laboratory tests); a 16-week treatment period 1 (parallel
arms: i.v. abatacept given on days 1, 14, 28 of period 1, and every 28
days thereafter vs. placebo at same time points); a switchover in
treatment in a second 16-week treatment period 2 (same adminis-
tration schedule as period 1); a 169-day abatacept open-label
extension (OLE) period; and a 6-month follow-up period.
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equivalent at doses # 10 mg/day), CNI (cyclosporine
and tacrolimus), or MMF or mycophenolic acid as long
as the dose has not changed for 4 weeks prior to
randomization. These agents were selected because
they are currently used to treat participants with FSGS
or MCD. The nonglucocorticoid agents must be used at
standard doses or to achieve therapeutic levels. These
restrictions on concomitant immunosuppressive agents
were based on prior experience with abatacept, to limit
potential additive toxicities, especially the risk of
serious infections. Participants will use either an
angiotensin-converting enzyme inhibitor or an angio-
tensin receptor blocker at stable doses during the
course of the double-blind period unless intolerant.
The dose of all concomitant medications can be
adjusted to address drug-related toxicity. Management
of hypertension and extracellular volume status will
follow standard of care.
Stratiﬁcation
Because APOL1 high-risk genetic variants have been
well described in patients with FSGS, we have elected
to control for different effects of treatment in patients
with different APOL1 risk status by stratifying par-
ticipations at randomization. This approach will ulti-
mately illuminate the generalizability of study ﬁndings
to those patients with and without high-risk APOL1
variants. All participants regardless of race will be
offered testing to screen for the single-nucleotide
polymorphisms associated with the high-risk APOL1
variants, risk allele G1 (rs73885319 and rs60910145)
and risk allele G2 (rs71785313). Genotyping will adhere
to Clinical Laboratory Improvement Amendments
(CLIA) quality standards (Gentris LLC, Charlotte, NC).
Genotyping during screening will not be necessary if
results of previous testing are available. Participants
with 2 copies of the high-risk APOL1 variants will be
in the APOL1 high-risk group, and those who do not
have 2 copies or who refuse screening for APOL1
variants will be in the other APOL1 stratiﬁcation
group. Randomization will also be stratiﬁed by age
(< 18 and $ 18 years).
Sample Size
This pilot study will randomize 90 participants to
assess the effect of abatacept versus placebo in the
primary endpoint, the proportion of participants who
achieve a renal response at day 113. A total of 90
participants randomized in a 1:1 ratio to abatacept and
placebo will provide approximately 80% power to
detect a treatment difference (delta) of 28% between
the 2 treatment arms, with a 2-sided alpha level of 5%.
We assume a renal response rate of 40% and 12% in
the abatacept and placebo arms, respectively. The 12%
estimate of renal response in the placebo arm was based
on expert opinion and the observed rate of renal
response in the Novel Therapies for Resistant FSGS
(FONT II) study,17 which enrolled a population similar
to the participants who will be entered into the aba-
tacept trial.
Analysis
An intention-to-treat (ITT) approach will be used for
analyses of the primary endpoint in period 1. It will
include all randomized and treated participants. For
participants who drop out or have missing data, we
will consider the participant to be a nonresponder. The
primary analysis of renal response will be performed
using a logistic regression model that includes treat-
ment arm, randomization stratiﬁcation factor (APOL1
genotype and age) and baseline UPCR as a continuous
variable. The treatment effect will be estimated by the
adjusted OR for treatment, with corresponding 95%
conﬁdence interval (CI) and P value. Sensitivity ana-
lyses (e.g., using a per protocol analysis set, alternative
imputation methods) will be performed to conﬁrm the
robustness of conclusions regarding the primary
endpoint.
Differences in the proportion of participants
achieving complete remission at day 113 will be the
main secondary efﬁcacy analysis. The same analytic
approach as for the primary endpoint will be used.
Other secondary endpoints that are measured at the
end of period 1 that are continuous (e.g., differences in
mean change from baseline in UPCR, serum albumin,
cholesterol, and triglycerides) will be analyzed using a
longitudinal (repeated-measure) mixed model,
including treatment group, baseline value of variable
and randomization stratiﬁcation factors, time, and
time-by-treatment interaction as ﬁxed effects and
participant as a random effect. The test of treatment
groupby-time interaction will provide the test of
whether treatment affects mean outcomes over the
course of study treatment.
For outcomes assessed in period 2 and the OLE
periods, including safety outcomes, descriptive statis-
tics will be provided. Other efﬁcacy analyses will
include analysis of proportions of participants in each
cohort who are in phase II and in relapse. A point
estimate of response rate, 95% conﬁdence interval,
point estimates, and 95% conﬁdence interval of treat-
ment difference adjusted for the 2 randomization
stratiﬁcation factors (based on minimum risk weights)
will be calculated.
DISCUSSION
In this report, we describe the design of a multicenter,
prospective, randomized clinical trial to test the efﬁ-
cacy of abatacept in the treatment of children and
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adults with treatment-resistant nephrotic syndrome
presumably caused by FSGS or MCD. Treatment-
resistant identiﬁes those patients who are either unre-
sponsive to or intolerant to existing therapies due to
unacceptably severe side effects. This group of patients
is at high risk for loss of kidney function and pro-
gression to ESKD. In the absence of a proven therapy,
this condition represents a pressing unmet need in the
clinical care of patients with glomerular disease. The
selection of the test agent is based on a body of pre-
clinical and translational research demonstrating that
the target protein, CD80, is expressed in podocytes and
interacts with b1 integrin on the podocyte cell surface,
leading to disruption of the actin cytoskeleton, foot
process effacement, and proteinuria.18 A small case
series detailed the course in patients with recurrent
FSGS in a kidney transplant (n ¼ 4) or disease in the
native kidneys (n ¼ 1) who responded to abatacept. In
contrast, Delville et al.19 detailed a series of 9 patients
with recurrent FSGS based on the development of
nephrotic-range proteinuria post transplantation who
failed to improve after abatacept treatment. Other case
reports have also described both response and failure of
response to abatacept in participants with native kid-
neys. There are case reports of patients with FSGS or
MCD who responded or failed to respond to abata-
cept.20–22 These conﬂicting data underscore the
importance of this randomized clinical trial to deter-
mine the efﬁcacy of abatacept in the management of
TRNS and of separating the treatment of native kidney
disease from the treatment of posttransplantation
recurrence.
MCD and FSGS represent heterogeneous conditions,
and it is unlikely that 1 intervention will be effective in
all patients. Similar to the approach that is being
applied in oncology, there is an increasing attempt to
categorize glomerular diseases by the underlying
biology to enable selection of patients who are most
likely to beneﬁt from a novel therapy. To make this
method practical, a biomarker proﬁle based on testing
of the kidney tissue or noninvasive assays of blood or
urine samples should be available that indicates
abnormal activity of the disease pathway. Unfortu-
nately, this is not yet available for the CD80 pathway,
and therefore this clinical trial does not incorporate
testing to identify patients who are more likely to
respond favorably to abatacept treatment as an eligi-
bility criterion.23 As a consequence, the sample size is
relatively large for a rare condition such as TRNS, and
we may fail to document beneﬁt with abatacept ther-
apy. Future research is needed to identify a validated
biomarker signature that will enable preselection of
patients for whom abatacept is an appropriate choice
for the treatment of resistant nephrotic syndrome.
Urine, serum, mRNA, and DNA samples will be
collected and stored in a study biorepository to facili-
tate the performance of ancillary studies with the goal
of identifying biomarkers that correlate with response
to abatacept.
Recruitment into trials of rare diseases is always a
challenge. Nephrology ranks near the bottom of med-
ical subspecialties in the implementation and comple-
tion of clinical trials.24 The nephrology community is
organizing to overcome this obstacle by establishing
consortia of nephrology practices that have strong
clinical experience in studies of patients with primary
glomerular disease. In addition, the switchover design,
escape option with ﬁrst relapse following the switch-
over, and OLE assures all patients that they will have
access to the test drug in a timely manner in both
randomized and extension periods. It is anticipated
that this will enhance patient acceptance of the proto-
col and promote steady enrollment into the trial. To
prevent period effects and potential bias based on the
escape with initial relapse for patients on randomized
therapy following the switchover, primary outcome
analysis will be restricted to the treatment response in
the ﬁrst phase of randomized treatment prior to
switchover.
Abatacept is already approved for use in patients
with rheumatoid arthritis and juvenile idiopathic
arthritis. It has been in use for more than a decade, and
it has a well-characterized safety proﬁle. We are pro-
posing to repurpose the drug and to expand its ther-
apeutic proﬁle to include glomerular disease. This is
consistent with current efforts to study this drug for
lupus nephritis, another rheumatologic condition
associated with proteinuric kidney disease, for which
abatacept is currently under evaluation in a random-
ized controlled phase III trial (NCT01714817). Because
our study of TRNS does not represent a ﬁrst-use-in-
humans trial, we anticipate that this will foster
greater enrollment by potential participants. Because
TRNS may alter the handling of drugs including
monoclonal antibodies with increased renal clearance,25
we have taken this into account in the selection of the
test dose. In addition, we will perform pharmacokinetic
studies to assess the relationship between exposure to
abatacept and the clinical response.
In conclusion, we describe the design of a pilot
randomized clinical trial to test the efﬁcacy of abatacept
in patients with TRNS. We have adopted a trial design
that should promote enrollment, and we will conduct
the study using a network of experienced academic
nephrology centers. We speciﬁcally intend for this
pilot study to guide the execution of subsequent
studies of abatacept, based on biomarkers derived from
analysis of biosamples from responders versus
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nonresponders in this pilot study. Future studies may
therefore use these speciﬁc biomarkers for patient
enrollment, thus greatly increasing the potential for a
substantial treatment effect. It is hoped that this trial
will spur the identiﬁcation of biomarkers of CD80
involvement in TRNS, and will initiate a precision
medicinebased approach to this serious kidney dis-
ease in which the selection of a therapeutic agent is
guided by the underlying disease mechanism operating
in each individual patient.
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